A Study of Oral Ibogaine in Opioid Withdrawal

Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal.

Topic Addiction Healthy Subjects Opioid Use Disorder

Compound Ibogaine Placebo

Country United Kingdom

Visit trial

Status Recruiting

Results Published No

Start date 01 April 2021

End date 10 August 2023

Chance of happening 89%

Phase Phase I Phase II

Design Blinded

Type Interventional

Generation Second

Participants 110

Sex All

Age 18- 55

Therapy No

Trial Details

Detailed description restricted as elements of this trial are part of a Phase 1 clinical trial.

NCT Number NCT05029401

Sponsors & Collaborators

DemeRx
DemeRx is a subsidiary of atai that aims to develop ibogaine for Opioid Use Disorder.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.